- Active not recruitingPHASE3
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
This study looks at a new medicine called sparsentan for IgA nephropathy (IgAN), a kidney disease. It compares sparsentan to a standard treatment (irbesartan) to see if it helps protect kidneys and reduce protein in the urine over about two years.
For: Immunoglobulin A NephropathyUnited States · Australia · Belgium - Ongoing, recruitingTherapeutic confirmatory (Phase III)
J2A-MC-GZGW: A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once Daily Oral Orforglipron Compared with Placebo in Adult Participants with Type 2 Diabetes and Inadequate Glycemic Control with Insulin Glargine, with or without Metformin and/or SGLT-2 Inhibitor (ACHIEVE-5)
This study is looking into a new daily tablet, orforglipron, for adults with type 2 diabetes. We want to see if it's better than a dummy pill at helping control blood sugar when taken with insulin glargine and other diabetes medicines.
For: Type 2 DiabetesRomania - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Combination Compared to Zibotentan Monotherapy as well as Zibotentan/Dapagliflozin and Zibotentan Monotherapy Compared to Placebo in Participants with Cirrhosis
This study is looking at how safe new drug combinations (Zibotentan with Dapagliflozin, or Zibotentan on its own) are for people with liver scarring (cirrhosis). Researchers want to see if these treatments help manage fluid build-up in the body, compared to a dummy pill.
For: Cirrhosis of the liver is a condition in which the liver is scarred and damagedBelgium · Slovakia · Czechia - Recruiting
DYNAMic Renal Assessment: NOvel Methods to Assess KIDNEY Functional Reserve
This study looks for better ways to measure how well kidneys work, especially in early kidney disease. It compares new tests with current methods to see how kidneys respond to stress, like after eating protein, aiming for earlier detection and better understanding of kidney health.
For: Chronic Kidney DiseasesUnited Kingdom - Ongoing, recruitingTherapeutic exploratory (Phase II)
A study to investigate the mechanistic effects of dapagliflozin alone or in combination with balcinrenone, compared to balcinrenone and placebo on body fluid and electrolyte handling and energy metabolism in participants over 50 years of age with chronic kidney disease (DapaBalci-Leap)
This study is looking at how two medicines, dapagliflozin and balcinrenone, might help people over 50 with moderate kidney disease. It checks how these medicines affect the body's fluids, salts, and energy use. We want to see if they can help manage kidney health.
For: Stage 3 chronic kidney diseaseGermany · France - Ongoing, recruitingTherapeutic use (Phase IV)
A Phase 4, Randomized, Open-Label, Active-Controlled Study to Investigate the Efficacy and Safety of Switching From Weekly Dulaglutide to Weekly Tirzepatide in Adults With Type 2 Diabetes
This study is looking at how well a new medicine, Tirzepatide, works for adults with type 2 diabetes when they switch from another medicine called Dulaglutide. Researchers want to see if the new medicine helps lower blood sugar and improve other health markers like weight.
For: Type 2 DiabetesRomania · Germany · Belgium - Ongoing, recruitingPhase III and phase IV (Integrated)
Initiation of angiotensin receptor-neprilysin inhibitor (ARNi) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) in patients with heart failure with reduced ejection fraction (HFrEF): the INITIATE-HFrEF randomized open-label trial
This study is looking at new ways to treat heart failure where the heart struggles to pump blood effectively. It compares different combinations of existing medicines to see which approach works best and is safest for patients over a six-month period.
For: Heart failure with reduced ejection fractionPortugal - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Two Part Phase IIa/b Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Dose ranging Study to Assess Efficacy, Safety, and Tolerability of the Combination of Zibotentan and Dapagliflozin, and Dapagliflozin Monotherapy Versus Placebo in Participants with Cirrhosis with Features of Portal Hypertension
This study looks at new ways to treat liver scarring (cirrhosis) that causes high pressure in the liver. We are testing a combination of two medicines, Zibotentan and Dapagliflozin, against Dapagliflozin alone or a dummy pill, to see if they can lower this pressure and are safe.
For: Liver cirrhosis with features of portal hypertension.Spain · Germany · Netherlands - Ongoing, recruitingTherapeutic confirmatory (Phase III)
J2A-MC-GZGS: A Phase 3, Open-Label Study of Once Daily Orforglipron Compared with Insulin Glargine in Adult Participants with Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4)
This study is testing a new medicine, Orforglipron, for adults with type 2 diabetes and who are overweight or obese. It's looking at how well it works compared to an insulin called Glargine to protect against heart problems.
For: Obesity · Chronic Kidney disease · Type 2 DiabetesGreece · Germany · Austria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A 40-week study comparing the efficacy and safety of once weekly IcoSema and daily insulin glargine 100 units/mL in participants with type 2 diabetes inadequately controlled on oral anti diabetic drugs. COMBINE 4
This study looks at a new once-a-week insulin treatment, IcoSema, for people with type 2 diabetes whose blood sugar isn't well controlled by their current medicines. It compares IcoSema to a daily insulin, glargine, to see which is better and safer.
For: Type 2 diabetesGreece · Italy · Poland - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects with IgA Nephropathy on Sodium-glucose Cotransporter-2 Inhibitors (SGLT2i) (The ASSIST study)
This study looks at a new medicine called atrasentan for people with a kidney condition called IgA nephropathy. It compares atrasentan with a dummy pill (placebo) to see if it helps reduce protein in the urine, even if participants are already taking another kidney medicine called an SGLT2 inhibitor.
For: NephrologySpain - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema) s.c. in doses 2.4/2.4 mg and 1.0/1.0 mg once weekly versus semaglutide 2.4 mg and 1.0 mg, cagrilintide 2.4 mg and placebo in participants with type 2 diabetes inadequately controlled on metformin with or without an SGLT2 inhibitor
This study is testing a new combination medicine, CagriSema, for people with type 2 diabetes. It's looking at whether this combined medicine is better at controlling blood sugar and helping with weight loss than existing treatments, including its individual components, semaglutide and cagrilintide.
For: Type 2 diabetesDenmark · Sweden · Slovakia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
J2A-MC-GZGV: A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Once Daily Oral Orforglipron Compared with Dapagliflozin in Adult Participants with Type 2 Diabetes and Inadequate Glycemic Control with Metformin (ACHIEVE-2)
This study looks at a new drug, orforglipron, for people with type 2 diabetes whose blood sugar isn't well controlled with metformin. It compares orforglipron with an existing drug, dapagliflozin, to see how well they lower blood sugar and if they're safe.
For: Type 2 DiabetesPoland · Germany - Ongoing, recruitingTherapeutic exploratory (Phase II)
Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema 2.4 mg/2.4 mg) once weekly versus semaglutide 2.4 mg, cagrilintide 2.4 mg and placebo in people with chronic kidney disease and type 2 diabetes living with overweight or obesity.
This study looks at a new combination medicine, CagriSema, for people with type 2 diabetes, kidney disease, and overweight or obesity. It compares CagriSema to existing treatments and a dummy medicine to see how it affects kidney health, weight, and blood sugar, while checking for side effects.
For: Chronic Kidney Disease · Type 2 diabetesSpain · Hungary · Poland - Ongoing, recruitingTherapeutic exploratory (Phase II)
Safety and efficacy of once-weekly subcutaneous and once-daily oral NNC0487-0111 in participants with type 2 diabetes – a dose finding study
This study is testing a new medicine, NNC0487-0111, for people with type 2 diabetes. It's looking at different ways to take the medicine (once a week shot or once a day pill) to see how safe and effective it is at controlling blood sugar.
For: Type 2 DiabetesRomania · Spain · Poland - AuthorisedTherapeutic use (Phase IV)
A multicenter, register-based, randomized, controlled trial comparing dapagliflozin with metformin treatment in early stage type 2 diabetes patients by assessing mortality and macro- and microvascular complications
This study compares two common diabetes medicines, dapagliflozin and metformin, for people recently diagnosed with type 2 diabetes. We want to see how these medicines affect serious health problems like heart attacks, strokes, kidney issues, and overall health over time.
For: Type 2 DiabetesSweden - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Impact of dapagliflozin on vascular function in chronic kidney disease patients - (DAPA-VASC)
This study is looking at how a medicine called dapagliflozin might affect blood vessels in people with long-term kidney disease. Researchers want to see if it improves how well blood vessels relax and widen over 12 weeks compared to a dummy pill.
For: chronic kidney disease patientsFrance - AuthorisedPhase I and Phase II (Integrated)- Other
A 6-Month, Randomized, Double-Blind Study to Evaluate the Effect of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with Chronic Kidney Disease (DECODE-CKD)
This study looks at how a medicine called dapagliflozin affects the heart in people with long-term kidney disease. Researchers want to see if it changes the heart's size and how well it pumps after six months. Half the people will get the medicine, and half will get a dummy pill.
For: Chronic kidney diseaseDenmark - AuthorisedTherapeutic confirmatory (Phase III)
Early start corticosteroids versus standard care (RASBs followed by corticosteroids) for proteinuria in Immunoglobulin A Nephropathy (IgAN) patients with active renal lesions identified by kidney biopsy and RASBs combined with corticosteroids versus sodium-glucose cotransporter2 inhibitor combined with RASBs for proteinuria and renal function in IgAN patients with chronic renal lesions identified by kidney biopsy. A PROJECT FOR TWO MULTICENTRE, PROSPECTIVE OPEN LABEL RANDOMIZED CLINICAL STUDIES TO EVALUATE THE EFFECT OF TARGETED THERAPY BASED ON KIDNEY BIOPSY FINDINGS IN IgAN PATIENTS (CLIgAN)
This study is looking at new ways to treat IgA nephropathy (IgAN), a kidney disease. It compares different medications like steroids and dapagliflozin to see how well they reduce protein in the urine and protect kidney function in people with IgAN, depending on their kidney biopsy results.
For: Idiopathic IgA nephropathy (IgAN)Italy - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Effect of dapagliflozin on serum magnesium in HNF1ß patients with renal hypomagnesemia
This study is looking at a medicine called dapagliflozin to see if it can help people with a specific genetic condition (HNF1beta mutation) who have low magnesium levels in their blood. We want to find out if this medicine can increase their magnesium.
For: Hypomagnesemia due to HNF1beta mutationNetherlands - Active not recruitingPHASE3
Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)
This study is looking into a new combination treatment (Zibotentan/Dapagliflozin) for chronic kidney disease with high protein levels in the urine. It compares this combination with an existing treatment (Dapagliflozin) to see if it's more effective and safe.
For: Chronic Kidney Disease With High ProteinuriaUnited States · Argentina · Australia